HK1061206A1 - Triazolo 4,5-d pyrimidine derivatives and their use as purinergic receptor antagonists - Google Patents

Triazolo 4,5-d pyrimidine derivatives and their use as purinergic receptor antagonists

Info

Publication number
HK1061206A1
HK1061206A1 HK04104319.2A HK04104319A HK1061206A1 HK 1061206 A1 HK1061206 A1 HK 1061206A1 HK 04104319 A HK04104319 A HK 04104319A HK 1061206 A1 HK1061206 A1 HK 1061206A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
aryl
disorder
formula
receptors
Prior art date
Application number
HK04104319.2A
Other languages
English (en)
Inventor
Roger John Gillespie
Joanne Lerpiniere
Suneel Gaur
Samantha Jayne Bamford
Gemma C Stratton
Stefania Leonardi
Scott Murray Weiss
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Publication of HK1061206A1 publication Critical patent/HK1061206A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK04104319.2A 2001-01-10 2004-06-15 Triazolo 4,5-d pyrimidine derivatives and their use as purinergic receptor antagonists HK1061206A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0100624.6A GB0100624D0 (en) 2001-01-10 2001-01-10 Chemical compounds VII
PCT/GB2002/000091 WO2002055083A1 (en) 2001-01-10 2002-01-10 TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
HK1061206A1 true HK1061206A1 (en) 2004-09-10

Family

ID=9906571

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04104319.2A HK1061206A1 (en) 2001-01-10 2004-06-15 Triazolo 4,5-d pyrimidine derivatives and their use as purinergic receptor antagonists

Country Status (27)

Country Link
US (3) US7141575B2 (no)
EP (1) EP1392312B1 (no)
JP (2) JP4287146B2 (no)
KR (1) KR100913845B1 (no)
CN (3) CN101691370A (no)
AT (1) ATE424207T1 (no)
AU (1) AU2002219355B2 (no)
BR (1) BR0206559A (no)
CA (1) CA2433453C (no)
CZ (1) CZ301916B6 (no)
DE (1) DE60231394D1 (no)
DK (1) DK1392312T3 (no)
ES (1) ES2323301T3 (no)
GB (1) GB0100624D0 (no)
HK (1) HK1061206A1 (no)
HR (1) HRP20030533A2 (no)
HU (1) HUP0401047A3 (no)
IL (2) IL156713A0 (no)
MX (1) MXPA03006165A (no)
NO (1) NO328475B1 (no)
NZ (1) NZ527248A (no)
PL (1) PL363101A1 (no)
PT (1) PT1392312E (no)
RS (1) RS51121B (no)
RU (1) RU2317084C2 (no)
WO (1) WO2002055083A1 (no)
ZA (1) ZA200305087B (no)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842424A1 (fr) * 2002-07-22 2004-01-23 Univ Paris 7 Denis Diderot Utilisation du nad ou de l'un de ses analogues, substrat des mono-adp-ribosyl tranferases, pour la preparation d'un medicament destine au traitement des pathologies liees aux recepteurs purinergiques
ES2354875T3 (es) 2002-12-19 2011-03-18 Schering Corporation Uso de antagonistas del receptor a2a de la adenosina para el tratamiento o prevención del síndrome extrapiramidal.
TWI375677B (en) 2003-04-23 2012-11-01 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
EA010160B1 (ru) 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
US7709492B2 (en) 2004-04-21 2010-05-04 Schering Corporation Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
AU2005287729A1 (en) 2004-09-22 2006-03-30 H. Lundbeck A/S 2-acylaminothiazole derivatives
CN100398542C (zh) * 2005-03-18 2008-07-02 北京大学 具有抗hiv活性的取代1,2,3-三唑并嘧啶新化合物，制备方法及用途
NZ561939A (en) * 2005-03-30 2011-03-31 Conforma Therapeutics Corp Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
US7851478B2 (en) * 2005-06-07 2010-12-14 Kyowa Hakko Kirin Co., Ltd. Agent for preventing and/or treating movement disorder
LT1921077T (lt) * 2005-08-02 2017-09-25 Kyowa Hakko Kirin Co., Ltd. Agentas, skirtas miego sutrikimo gydymui ir (arba) prevencijai
CN101312978A (zh) 2005-09-19 2008-11-26 先灵公司 作为腺苷A2a受体拮抗剂的2－杂芳基－吡唑并－[4,3－e]－1,2,4－三唑并－[1,5－c]－嘧啶
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
DE102005049954A1 (de) * 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
WO2007149211A1 (en) * 2006-06-22 2007-12-27 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
JP2010515690A (ja) * 2007-01-05 2010-05-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 医薬品の多形及び溶媒和物、並びに製造方法
EP2117313A4 (en) * 2007-01-12 2011-04-27 Biogen Idec Inc PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEM
FR2915197B1 (fr) * 2007-04-18 2009-06-12 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
FR2915199B1 (fr) * 2007-04-18 2010-01-22 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2915198B1 (fr) * 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
EP2262811B1 (en) 2008-03-04 2016-04-27 Merck Sharp & Dohme Corp. 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e]-1,2,4-triazolo [4,3-c]pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
JP2011514350A (ja) 2008-03-04 2011-05-06 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するためのアミノ−キノキサリンおよびアミノ−キノリン化合物
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
WO2009152521A2 (en) * 2008-06-13 2009-12-17 Parkinson's Institute Diagnosis of neurodegenerative disorders
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
NZ590793A (en) * 2008-07-23 2012-07-27 Kyowa Hakko Kirin Co Ltd Therapeutic agent for migraine
NZ593418A (en) * 2008-12-24 2013-10-25 Bial Portela & Ca Sa Imidazole compounds for use as enzyme inhibitors
BRPI1009398A2 (pt) 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
WO2011050160A1 (en) * 2009-10-22 2011-04-28 Biogen Idec Ma Inc. Pharmaceuticals, compositions and methods of making and using the same
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
EP2509983B1 (en) 2009-11-16 2014-09-17 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
EP2531492B1 (en) 2010-02-05 2016-04-13 Heptares Therapeutics Limited 1,2,4-triazine-4-amine derivatives
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
AU2016379425B2 (en) 2015-12-24 2021-11-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
CN107021963A (zh) * 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
KR20190104528A (ko) 2016-12-03 2019-09-10 주노 쎄러퓨티크스 인코퍼레이티드 Car-t 세포들 투여를 결정하는 방법
CN110248678A (zh) 2016-12-03 2019-09-17 朱诺治疗学股份有限公司 调节car-t细胞的方法
CN106883191A (zh) * 2017-01-19 2017-06-23 华侨大学 一种n‑取代苯并三氮唑衍生物的制备方法
EP3594216B1 (en) * 2017-03-07 2022-04-06 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof
US10654825B2 (en) 2017-03-30 2020-05-19 Corvus Pharmaceuticals, Inc. Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereof
US11040040B2 (en) 2017-04-04 2021-06-22 Corvus Pharmaceuticals, Inc. Methods of treating cancer
WO2018187791A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
EP3630132A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
CN111902159A (zh) 2017-11-01 2020-11-06 朱诺治疗学股份有限公司 对b细胞成熟抗原（bcma）具有特异性的嵌合抗原受体
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CN111989106A (zh) 2017-12-01 2020-11-24 朱诺治疗学股份有限公司 基因工程化细胞的给药和调节方法
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
US20200316077A1 (en) 2017-12-19 2020-10-08 Impetis Biosciences Ltd. Pharmaceutical composition for the treatment of cancer
CA3087655A1 (en) 2018-01-04 2019-07-11 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
WO2020005873A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
WO2020014666A1 (en) 2018-07-12 2020-01-16 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
WO2020068583A1 (en) * 2018-09-27 2020-04-02 Corvus Pharmaceuticals, Inc. Processes for making triazolo [4,5d] pyramidine derivatives and intermediates thereof
MA54078A (fr) 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
JP2022506598A (ja) 2018-11-01 2022-01-17 ジュノー セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
WO2020102770A1 (en) 2018-11-16 2020-05-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
SG11202105502RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for treatment using adoptive cell therapy
JP2022518925A (ja) 2019-01-29 2022-03-17 ジュノー セラピューティクス インコーポレイテッド 受容体チロシンキナーゼ様オーファン受容体１（ｒｏｒ１）に特異的な抗体およびキメラ抗原受容体
CN110251518A (zh) * 2019-06-28 2019-09-20 青岛科技大学 1,2,4-三氮唑类杂环化合物在制备预防或治疗与中枢系统相关疾病药物中的应用
CN112592354B (zh) 2019-07-30 2022-05-27 厦门宝太生物科技股份有限公司 一种异噁唑并嘧啶类杂环化合物的制备方法
CN112479956A (zh) 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法
WO2021050688A1 (en) * 2019-09-10 2021-03-18 X-Chem, Inc. Compounds and uses thereof
KR20220066332A (ko) * 2019-10-22 2022-05-24 알파라 컴퍼니 리미티드 피리미딘 아미드 화합물 및 이의 용도
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024129778A2 (en) 2022-12-13 2024-06-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56131587A (en) 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd 7-substituted triazolopyrimidine derivative and its preparation
JPS56131586A (en) 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd Triazolopyrimidine derivative and its preparation
JPS5962595A (ja) 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５，７―トリ置換―トリアゾロピリミジン誘導体
DE3304330A1 (de) 1983-02-09 1984-08-09 Basf Ag, 6700 Ludwigshafen Neue 2h-v-triazolyl(4,5-d)-pyrimidine und deren verwendung
JPS60140335A (ja) 1983-12-28 1985-07-25 Konishiroku Photo Ind Co Ltd 熱現像カラ−感光材料
US5204353A (en) 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
US5194581A (en) 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
CZ101496A3 (en) 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
JP4084415B2 (ja) 1995-07-11 2008-04-30 アストラゼネカ・アクチエボラーグ 新しい血小板凝集抑制剤
ZA971896B (en) * 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
EP0923582B1 (en) * 1996-08-28 2006-09-20 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
CA2284737C (en) * 1997-03-24 2007-03-13 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]triazolo[1,5-c]pyrimidine derivatives
US5912225A (en) * 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
HUP0001299A3 (en) * 1997-04-30 2001-09-28 Univ Johns Hopkins Med Biodegradable compositions comprising poly(cycloaliphatic phosphoester) compounds and articles
US6028163A (en) 1997-06-27 2000-02-22 Guilford Pharmaceuticals Inc. Solution polymerization of high molecular weight poly(phosphoesters) in toluene
EP0994860A1 (en) 1997-07-03 2000-04-26 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
AU1251499A (en) 1997-11-26 1999-06-15 Cerebrus Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
CA2315736A1 (en) 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
KR100694684B1 (ko) 1999-07-02 2007-03-13 에자이 알앤드디 매니지먼트 가부시키가이샤 축합 이미다졸 화합물 및 당뇨병 치료약

Also Published As

Publication number Publication date
JP2009102337A (ja) 2009-05-14
CN1496262A (zh) 2004-05-12
KR20030076998A (ko) 2003-09-29
IL156713A (en) 2011-04-28
MXPA03006165A (es) 2003-09-16
IL156713A0 (en) 2004-01-04
US7405219B2 (en) 2008-07-29
CA2433453A1 (en) 2002-07-18
CN101214248A (zh) 2008-07-09
US20080234296A1 (en) 2008-09-25
US7141575B2 (en) 2006-11-28
GB0100624D0 (en) 2001-02-21
DE60231394D1 (de) 2009-04-16
HUP0401047A2 (hu) 2004-09-28
US20040097526A1 (en) 2004-05-20
DK1392312T3 (da) 2009-06-15
EP1392312A1 (en) 2004-03-03
JP4287146B2 (ja) 2009-07-01
RS51121B (sr) 2010-10-31
ATE424207T1 (de) 2009-03-15
YU55503A (sh) 2006-05-25
BR0206559A (pt) 2004-06-22
RU2317084C2 (ru) 2008-02-20
NO328475B1 (no) 2010-03-01
JP2004517862A (ja) 2004-06-17
CZ20031955A3 (cs) 2004-01-14
NZ527248A (en) 2004-05-28
CN101691370A (zh) 2010-04-07
US7589097B2 (en) 2009-09-15
NO20033146L (no) 2003-09-09
WO2002055083A1 (en) 2002-07-18
HUP0401047A3 (en) 2007-12-28
EP1392312B1 (en) 2009-03-04
PL363101A1 (en) 2004-11-15
NO20033146D0 (no) 2003-07-09
ES2323301T3 (es) 2009-07-13
ZA200305087B (en) 2004-07-12
CZ301916B6 (cs) 2010-07-28
KR100913845B1 (ko) 2009-08-26
JP5202259B2 (ja) 2013-06-05
PT1392312E (pt) 2009-06-12
US20070049607A1 (en) 2007-03-01
CA2433453C (en) 2010-06-08
HRP20030533A2 (en) 2005-06-30
RU2003124651A (ru) 2005-01-27
AU2002219355B2 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
HK1061206A1 (en) Triazolo 4,5-d pyrimidine derivatives and their use as purinergic receptor antagonists
DE60228414D1 (de) Pyrrolo 2,3-d pyrimidine und deren verwendung als purinreceptor antagonisten
YU55603A (sh) Derivati purina kao antagonisti purinergiskog receptora
ATE407935T1 (de) Thieno(3,2-d)pyrimidine und furano(3,2- d)pyrimidine und deren verwendung als antagonisten an purinergen rezeptoren
AU781323B2 (en) Anti-viral pyrimidine nucleoside analogues
PE20010430A1 (es) DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a
HUP0301614A2 (hu) Pirido[2,3-D]pirimidin és pirimido[4,5-D]pirimidin nukleozidok
NO20055510L (no) 2-alkynyl- og 2-alkenylpyrazolo [4,3-E]-1,2,4-triazolo-[1,5-C]-pyrimidin-adenosin A2A-reseptorantagonister
NZ510629A (en) [1,2,4]Triazolo[1,5-c]pyrimidine derivatives and pharmaceutical use as adenosine A2A receptor antagonists
TW200745130A (en) 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
AU2890497A (en) Nucleoside derivatives with photolabile protective groups
CA2543431A1 (en) Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
WO2003020723A1 (fr) Derive de [1,2,4]triazolo[1,5-a]pyrimidine
ATE238334T1 (de) Nucleosid-derivate mit photolabilen schutzgruppen
WO2003028712A3 (en) Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
Liu et al. Condensed 1, 3‐benzothiazinones. 1. Facile synthesis of 2‐amino‐1, 2, 4‐triazolo [5, 1‐b][1, 3]‐benzothiazin‐9‐one
TH152248A (th) 2-อัลไคนิล-และ 2-อัลคีนิล-ไพราโซโล-[4,3-e]-1,2,4-ไตรอะโซโล-[1,5-c]-ไพริมิดีน ที่เป็นแอนทาโกนิสท์ของตัวรับอะดีโนซีนA2a

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130110